FDA approves Genmab’s ofatumumab for relapsed CLL
The US Food and Drug Administration (FDA) has approved Genmab’s ofatumumab (Arzerra), in combination with fludarabine and cyclophosphamide (FC), to treat patients with relapsed chronic lymphocytic leukaemia (CLL).
Click on this link for more information.
